Key clinical point: First-line dual immune checkpoint inhibition with nivolumab and ipilimumab has durable efficacy in advanced melanoma.
Major finding: Median overall survival was 19.9 months with ipilimumab alone versus more than 60.0 months (not reached) with nivolumab-ipilimumab (hazard ratio for death, 0.52) and 36.9 months with nivolumab alone (HR, 0.63).
Study details: A 5-year update of the phase 3, randomized, controlled CheckMate 067 trial among 945 adults with previously untreated or unresectable metastatic melanoma.
Disclosures: Dr. Larkin disclosed grants and personal fees from numerous pharmaceutical companies. The trial was supported by Bristol-Myers Squibb, a grant from the National Cancer Institute, and a grant (to Dr. Larkin) from the National Institute for Health Research Royal Marsden–Institute of Cancer Research Biomedical Research Centre.
Larkin J et al. N Engl J Med. 2019 Sep 28..